|
gptkbp:instanceOf
|
opioid
semisynthetic opioid
|
|
gptkbp:abusePotential
|
high
|
|
gptkbp:ATCCode
|
N02AA05
|
|
gptkbp:bioavailability
|
60–87% (oral)
|
|
gptkbp:brand
|
gptkb:Percocet
gptkb:Roxicodone
gptkb:OxyContin
|
|
gptkbp:CASNumber
|
76-42-6
|
|
gptkbp:contraindication
|
paralytic ileus
acute or severe bronchial asthma
severe respiratory depression
known hypersensitivity to oxycodone
|
|
gptkbp:controlledBy
|
gptkb:DEA_(US)
gptkb:TGA_(Australia)
gptkb:Health_Canada
gptkb:EMA_(Europe)
|
|
gptkbp:derivedFrom
|
gptkb:thebaine
|
|
gptkbp:developedBy
|
gptkb:Germany
|
|
gptkbp:discoveredBy
|
gptkb:Edmund_Speyer
gptkb:Martin_Freund
|
|
gptkbp:discoveredIn
|
1916
|
|
gptkbp:eliminationHalfLife
|
3–4.5 hours (immediate-release)
4.5–6.5 hours (extended-release)
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstMarketedYear
|
1917
|
|
gptkbp:hasMolecularFormula
|
C18H21NO4
|
|
gptkbp:hasStreet
|
gptkb:OC
gptkb:hillbilly_heroin
oxy
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
oxycodone
|
|
gptkbp:KEGGID
|
gptkb:D08342
|
|
gptkbp:legalStatus
|
Prescription only (various countries)
Schedule II controlled substance (US)
|
|
gptkbp:marketedAs
|
gptkb:Germany
|
|
gptkbp:mechanismOfAction
|
mu-opioid receptor agonist
|
|
gptkbp:MeSH_ID
|
gptkb:D010059
|
|
gptkbp:metabolism
|
gptkb:CYP2D6
gptkb:CYP3A4
gptkb:noroxycodone
gptkb:6-oxycodol
gptkb:noroxycodol
gptkb:noroxymorphone
gptkb:oxymorphone
liver
|
|
gptkbp:partOf
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
45%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL44961
4447447
5284603
DB00497
|
|
gptkbp:riskFactor
|
addiction
overdose
respiratory depression
withdrawal symptoms
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
subcutaneous
intravenous
rectal
|
|
gptkbp:sideEffect
|
nausea
constipation
dizziness
itching
drowsiness
|
|
gptkbp:UNII
|
C5DOXJ6SLL
|
|
gptkbp:usedFor
|
pain management
|
|
gptkbp:bfsParent
|
gptkb:Thebaine
gptkb:opioid
gptkb:Percs
|
|
gptkbp:bfsLayer
|
6
|